Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 671-678

  Lynch Jr , Joseph J ^a   Wallace, Audrey A ^a   Stump, Gary L ^a   Stupienski III, Raymond F ^a   Kothstein, Theresa ^a   Gehret, John R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL;

ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BENZOPYRANS; DOGS; ELECTROCARDIOGRAPHY; FEMALE; HEART; MALE; MYOCARDIAL INFARCTION; PIPERIDINES;

EID: 0030423735     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. BILLMAN, G. E.: Effect of calcium channel antagonists on susceptibility to sudden cardiac death: Protection from ventricular fibrillation. J. Pharmacol. Exp. Ther. 248: 1334-1342, 1989.
2. BLACK, S. C., BUTTERFIELD, J. L. AND LUCCHESI, B. R.: Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a Class III antiarrhythmic drug. J. Cardiovasc. Pharmacol. 22: 810-818, 1993.
3. BLACK, S. C., CHI, L., MU, D.-X. AND LUCCHESI, B. R.: The antifibrillatory actions of UK-68,798, a Class III antiarrhythmic agent. J. Pharmacol. Exp. Ther. 258: 416-423, 1991.
4. CHI, L , MU, D.-X., DRISCOLL, E. M. AND LUCCHESI, B. R.: Antiarrhythmic and electrophysiologic actions of CK-3579 and sematilide in a conscious canine model of sudden coronary death. J. Cardiovasc. Pharmacol. 16: 312-324, 1990.
5. CHI, L., MU, D.-X. AND LUCCHESI, B. R.: Electrophysiology and antiarrhythmic actions of E-4031 in the experimental animal model of sudden coronary death. J. Cardiovasc. Pharmacol. 17: 285-295, 1991.
6. Kr potassium channel blockers as Class III antiarrhythmic agents. In: Perspectives in Medicinal Chemistry, ed by B. Testa, E. Kyburz, W. Fuhrer, R. Giger, ed. Verlag Helvetica Chimica Acta, Basel, 389-404, 1993.
7. COBBE, S. M., HOFFMAN, E., RITZENHOFF, A , BRACHMANN, J., KUBLER, W. AND SENGES, J.: Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase. Circulation 68: 865-871, 1983.
8. COLATSKY, T. J. AND ARGENTIERI, T. M.: Potassium channel blockers as antiarrhythmic drugs. Drug Dev. Res. 33: 235-249, 1994.
9. DAVIS, J., GLASSMAN, R., AND WIT, A. L.: Method for evaluating the effects of antiarrhythmic drugs on ventricular tachycardias with different electrophysiologic characteristics and different mechanisms in the infarcted canine heart. Am. J. Cardiol. 49: 1176-1184, 1982.
10. DE BAKKER, J. M. T., VAN CAPELLE, F. J. L., JANSE, M. J., WILDE, A. A. M., CORONEL, R., BECKER, A. E., DINGEMANS, K. P., VAN HEMEL, N. M. AND HAUER, R. N. W.: Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: Electrophysiologic and anatomic correlation. Circulation 77: 589-606, 1988.
11. DOWNAR, E., HARRIS, L., MICKLEBOROUGH, L. L., SHAIKH, N. AND PARSON, I. D.: Endocardial mapping of ventricular tachycardia in the intact human ventricle. Evidence for reentrant mechanisms. J. Am. Coll. Cardiol. 11: 783-791, 1988.
12. ECHT, D. S., GRIFFIN, J. C., FORD, A. J., KNUTTI, J. W., FELDMAN, R. C. AND MASON, J. W.: Nature of inducible ventricular tachyarrhythmias in a canine chronic myocardial infarction model. Am. J. Cardiol. 52: 1127-1132, 1983.
13. FELD, G. K., FLECK, R. P., CHEN, P.-S., BOYCE, K., BAHNSON, T. D., STEIN, J. B., CALISI, C. M. AND IBARRA, M.: Radiofrequency catheter ablation for the treatment of human type I atrial flutter. Identification of a critical zone in the reentrant circuit by endocardial mapping techniques. Circulation 86: 1233-1240, 1992.
14. FERRARI, G. M , SALVATI, P., GROSSONI, M., UKMAR, G , VAGA, L., PATRONO, C. AND SCHWARTZ, P. J.: Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. J. Am. Coll. Cardiol. 21: 283-290, 1993.
15. FISHBEIN, M. C., MEERBAUM, S., RIT, J., LANDO, U., KANMATSUSE, K., MERCIER, J. C., CORDAY, E. AND GANZ, W.: Early phase acute myocardial infarct size quantitation. Validation of the triphenyltetrazolium chloride tissue enzyme staining technique. Am. Heart J. 101: 593-600, 1981.
16. FREEDMAN, R. A., KARAGOUNIS, L. A. AND STEINBERG, J. S.: Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia. Relation to suppression of inducibility and changes in tachycardia cycle length. J. Am. Coll. Cardiol. 20: 1213-1219, 1992
17. FURUKAWA, T., ROZANSKI, J. J , MOROE, K., GOSSELIN, A. J. AND LISTER, J. W.: Efficacy of procainamide on ventricular tachycardia. Relation to prolongation of refractoriness and slowing of conduction Am. Heart J. 118: 702-708, 1989.
18. GOLDBERG, M. R., PORRAS, A. G., GREBER, T. F., SOMERS, G., PRUITT, L. AND DESMET, M.: MK-499: Plasma concentrations and sustained effects on QTc interval in healthy volunteers (Abstract). Clin Pharmacol. Ther. 55: 158, 1994.
19. HOLLAND, K., PATTERSON, E. AND LUCCHESI, B. R.: Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. Am. Heart J. 105: 711-717, 1983.
20. HOPSON, J. R., KIENZLE, M. G., ASCHOFF, A. M. AND SHIRKEY, D. R.: Noninvasive prediction of efficacy of Type IA antiarrhythmic drugs by the signal-averaged electrocardiogram in patients with coronary artery disease and sustained ventricular tachycardia. Am. J. Cardiol. 72: 288-293, 1993.
21. KATOH, H., OGAWA, S., FURUNO, I., SATO, Y., YOH, S , SAEKI, K. AND NAKAMURA, Y.: Electrophysiological effects of E-4031, a Class III antiarrhythmic agent, on reentrant ventricular arrhythmias in a canine 7 day old myocardial infarction model. J. Pharmacol. Exp. Ther. 253: 1077-1082, 1990.
22. KLEIN, G. J., GUIRADON, G. M., SHARMA, A. D. AND MILSTEIN, S.: Demonstration of macroreentry and feasibility of operative therapy in the common type of atrial flutter. Am. J. Cardiol. 57: 587-591, 1986
23. KONINGS, K. T. S., KIRCHHOF, C. J. H. J., SMEETS, J. R. L. M., WELLENS, H J J., PENN, O. C. AND ALLESSIE, M. A.: High-density mapping of electrically-induced atrial fibrillation in humans. Circulation 89: 1665-1680, 1994.
24. KOU, W. H , NELSON, S. D., LYNCH, J. J., MONTGOMERY, D. G., DICARLO, L. AND LUCCHESI B. R.: Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period. Evaluation in a conscious canine model of sudden death. J. Am. Coll. Cardiol. 9: 359-365, 1987.
25. KRUMPL, G., TODT, H., KREJCY, K. AND RABERGER, G.: Antiarrhythmic efficacy of labetalol as assessed by programmed electrical stimulation. Br. J. Pharmacol. 100: 855-861, 1990.
26. KUS, T., CAMPA, M. A., NADEAU, R., DUBUC, M., KALTENBRUNNER, W. AND SHENASA, M.: Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. Am. Heart J. 123: 82-89, 1992.
27. KUS, T., COSTI, P., DUBUC, M. AND SHENASA, M.: Prolongation of ventricular refractoriness by Class IA antiarrhythmic drugs in the prevention of ventricular tachycardia induction. Am. Heart J. 120: 855-863, 1990.
28. LYNCH, J. J., COSKEY, L. A., MONTGOMERY, D. G. AND LUCCHESI, B. R.: Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. Am. Heart J. 109: 949-958, 1985.
29. LYNCH, J. J., HEANEY, L. A., WALLACE, A. A., GEHRET, J. R., SELNICK, H. G. AND STEIN, R. B.: Suppression of lethal ischemic ventricular arrhythmias by the Class III agent E-4031 in a canine model of previous myocardial infarction. J. Cardiovasc. Pharmacol. 15: 764-775, 1990a.
30. LYNCH, J. J., HEANEY, L. A., WALLACE, A. A., GEHRET, J. R. AND STEIN, R. B.: Failure of lidocaine to suppress lethal ischemic ventricular arrhythmias in a canine model of previous myocardial infarction. J. Cardiovasc. Pharmacol. 16: 41-49, 1990b.
31. LYNCH, J. J., WALLACE, A. A., STUPIENSKI, R. F., BASKIN, E. P., BEARE, C. M., APPLEBY, S. D., SALATA, J. J., JURKIEWICZ, N. K., SANGUINETTI, M. C., STEIN, R. B., GEHRET, J. R., KOTHSTEIN, T., CLAREMON, D. A., ELLIOTT, J. M., BUTCHER, J. W., REMY, D. C. AND BALDWIN, J. J.: Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine Class III agents, L-702,958 and L-706,000 [MK-499]. J. Pharmacol Exp. Ther. 269: 541-554, 1994.
32. LYNCH, J. J., WILBER, D. J., MONTGOMERY, D. G., HSIEH, T. M., PATTERSON, E. AND LUCCHESI, B. R.: Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol. J. Cardiovasc. Pharmacol. 6: 1132-1141, 1984.
33. MORGAN, T. K. AND SULLIVAN, M. E.: An overview of Class III electrophysiological agents: A new generation of antiarrhythmic therapy. Prog. Med. Chem. 29: 65-108, 1992.
34. MYERBURG, R. J., KESSLER, K. M. AND CASTELLANOS, A.: Cardiovascular collapse, cardiac arrest and sudden death. In: Harrison's Principles of Internal Medicine, ed. by K. J. Isselbacher, E. Braunwald, J. D. Wilson, J. B. Martin, A. S. Fauci, and D. L. Kasper., ed. pp. 193-198, McGraw-Hill, New York, 1994.
35. PATTERSON, E., HOLLAND, K., ELLER, B. T. AND LUCCHESI, B. R.: Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction. A conscious canine model of sudden cardiac death. Am. J. Cardiol. 50: 1414-1423, 1982.
36. PATTERSON, E. AND LUCCHESI, B. R.: Quinidine gluconate in chronic myocardial ischemic injury. Differential effects in response to programmed stimulation and acute myocardial ischemia in the dog (Abstract). Circulation 68: III-155, 1983.
37. PATTERSON, E., LYNCH, J. J. AND LUCCHESI, B. R.: Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist D,L-sotalol. J. Pharmacol. Exp. Ther. 230: 519-526, 1984.
38. POGWIZD, S. M., HOYT, R. H., SAFFFTZ, J. E., CORR, P. B., COX, J. L. AND CAIN, M. E.: Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation 86: 1872-1887, 1992.
39. RODEN, D. M.: Current status of Class III antiarrhythmic therapy. Am. J. Cardiol. 72: 44B-19B, 1993.
40. SAGER, P., NADEMANEE, K., SINGH, S., AHMED, R., ATTIN, M., BAILEY, W., GODFREY, R., EDWARDS, J., COLAMESTA, R. AND FRAME, V.: Electrophysiologic actions and lack of reverse frequency-dependence of MK-499 in humans (Abstract). PACE 17: 829, 1994.
41. SCHWARTZ, P. J., BILLMAN, G. E. AND STONE, H. L.: Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation 69: 790-300, 1984.
42. SINGH, B. N.: Controlling cardiac arrhythmias: To delay conduction or to prolong refractoriness. Cardiovasc. Drugs Ther. 3: 671-674, 1989.
43. SINGH, B. N. AND AHMED, R.: Class III antiarrhythmic drugs. Curr. Opin. Cardiol. 9: 12-22, 1994.
44. SINGH, B. N., ELLENBOGEN, K. A., ZOBLE, R. G., KIENZLE, M. G., JOHN, R. M., SOHAAL, S. F., SINGH, S. N., KLINGER, G. H. AND FRAME, V. B.: Electrocardiographic effects of oral MK-499, a new Class III antiarrhythmic drug, in patients with coronary artery disease (Abstract). J. Am. Coll. Cardiol. 23: 92A, 1994.
45. STEVENSON, W. G., KHAN, H., SAGER, P., SAXON, L. A., MIDDLEKAUF, H. R., NATTERSON, P. D. AND WIENER, I.: Identification of reentrant circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation 88: 1647-1670, 1993.
46. VAUGHAN WILLLAMS, E. M.: A classification of antiarrhythmic drugs reassessed after a decade of new drugs. J. Clin Pharmacol. 24: 129-147, 1984.
47. VAUGHAN WILLIAMS, E. M.: Delayed ventricular repolarization as an antiarrhythmic principle. Eur. Heart J. 6: suppl. D, 145-149, 1985.
48. VIVALDI, M. T., KLONER, R. A. AND SCHOEN, F. J.: Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am. J. Pathol. 121: 522-530, 1985.
49. WILBER, D. J., LYNCH, J. J., MONTGOMERY, D. AND LUCCHESI, B. R.: Postinfarction sudden death: Significance of inducible ventricular tachycardia and infarct size in a conscious canine model. Am. Heart J. 109: 8-18, 1985.
50. YOUNG, G. D., KERR, C. R., MOHAMA, R , BOONE, J. AND YEUNG-LAI-WAH, J. A.: Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. Am. J. Cardiol. 73: 677-682, 1994.
51. ZUANETTI, G. AND CORR, P. B.: Antiarrhythmic efficacy of a new Class III agent, UK-68,798, during chronic myocardial infarction. Evaluation using three-dimensional mapping. J. Pharmacol. Exp. Ther. 256: 325-334, 1991.